Australia markets open in 1 hour 57 minutes

TFF Pharmaceuticals, Inc. (TFFP)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.03-0.41 (-6.37%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close6.44
Bid5.97 x 1300
Ask6.03 x 1200
Day's range5.47 - 6.34
52-week range5.47 - 20.54
Avg. volume193,570
Market cap152.992M
Beta (5Y monthly)2.11
PE ratio (TTM)N/A
EPS (TTM)-1.15
Earnings date08 Mar 2022 - 14 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est21.67
  • Simply Wall St.

    TFF Pharmaceuticals, Inc. (NASDAQ:TFFP): Are Analysts Optimistic?

    We feel now is a pretty good time to analyse TFF Pharmaceuticals, Inc.'s ( NASDAQ:TFFP ) business as it appears the...

  • GlobeNewswire

    TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients

    Final Safety and Pharmacokinetic Data Continue to Support Progression to Phase 2 in the Near Term for Treatment of Invasive Pulmonary Aspergillosis (IPA), Including Patients with Mild to Moderate Asthma Pharmacokinetic Data Revealed No Differences in Patients Using Bronchodilators Compared to Healthy Subjects; Allows for Inclusion of Broader Patient Populations in Upcoming Phase 2 Studies Company Expects to Generate Phase 2 Data in IPA in 2022; Data Suggest Potential Utility in Treating Allergic

  • GlobeNewswire

    TFF Pharmaceuticals Hosting Science Day on December 13, 2021

    AUSTIN, Texas, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will host a science day related to two of the company’s lead assets, inhaled voriconazole for invasive pulmonary aspergillosis (IPA) and inhaled AUG-3387 for COVID-19, on Monday, December 13, 2021 from 1:30p